Pipeline

Sydnexis has fully enrolled the STAAR Study, its single pivotal Phase 3 study to treat the progression of myopia in children. The STAAR Study is a multi-center, randomized, double masked, placebo-controlled trial evaluating two dosage strengths of SYD-101 in more than 850 children between the ages of 3-14. To learn more about the STAAR Study, please visit the ClinicalTrials.gov website.

Pipeline

Sydnexis has fully enrolled the STAAR Study, its single pivotal Phase 3 study to treat the progression of myopia in children. The STAAR Study is a multi-center, randomized, double masked, placebo-controlled trial evaluating two dosage strengths of SYD-101 in more than 850 children between the ages of 3-14. To learn more about the STAAR Study, please visit the ClinicalTrials.gov website.